Samsung Biologics Signs Contract for Contract Manufacturing and Supply of Pharmaceuticals with AstraZeneca
[Asia Economy Reporter Oh Ju-yeon] Samsung Biologics announced on the 22nd that it has signed a pharmaceutical contract manufacturing supply agreement worth 18.638 billion KRW with AstraZeneca UK Ltd. This corresponds to 2.66% of recent sales.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Separately, it also announced that it has signed a pharmaceutical contract manufacturing supply agreement worth 366.327 billion KRW. This corresponds to 52.21% of recent sales. Regarding this matter, the company explained, "This contract is the main contract for the original drug contract manufacturing related to the 'Major Management Matters for Investment Judgment' announced on June 24, and the start date of the contract period (June 23) is recorded as the date of signing the letter of intent for the pharmaceutical contract manufacturing agreement."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
